Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Articles published by Teva Pharmaceutical Industries Ltd
Teva Reaffirms “Pivot to Growth” Strategy Progress with Launch of Acceleration Phase at 2025 Innovation and Strategy Day
May 29, 2025
From
Teva Pharmaceutical Industries Ltd
Via
GlobeNewswire
Tickers
TEVA
Teva Celiac Disease Candidate Granted Fast Track Designation by US FDA
May 27, 2025
From
Teva Pharmaceutical Industries Ltd
Via
GlobeNewswire
Tickers
TEVA
Teva to Present at Jefferies Global Healthcare Conference and Goldman Sachs Global Healthcare Conference in June
May 27, 2025
From
Teva Pharmaceutical Industries Ltd
Via
GlobeNewswire
Tickers
TEVA
Teva and Biolojic Design Initiate IND-enabling Studies of BD9, a Multibody Designed to Explore the Treatment of Atopic Dermatitis and Asthma
May 27, 2025
From
Teva Pharmaceutical Industries Ltd
Via
GlobeNewswire
Tickers
TEVA
Teva Announces Increase of the Maximum Tender Amount of its Debt Tender Offer and Increases to Pool Tender Caps for Pool 2 Notes and Pool 3 Notes
May 22, 2025
From
Teva Pharmaceutical Industries Ltd
Via
GlobeNewswire
Tickers
TEVA
Teva Announces Successful Upsizing and Pricing of $2,300,000,000 (Equivalent) Senior Notes; Proceeds to Repay Existing Debt
May 20, 2025
From
Teva Pharmaceutical Industries Ltd
Via
GlobeNewswire
Tickers
TEVA
Fitch Ratings Agency Upgrades Teva Rating to BB+ Recognizing Successful Execution of Its Pivot to Growth Strategy
May 20, 2025
From
Teva Pharmaceutical Industries Ltd
Via
GlobeNewswire
Tickers
TEVA
Teva Announces $2,000,000,000 (Equivalent) Debt Tender Offers For Notes Due 2026-2031
May 19, 2025
From
Teva Pharmaceutical Industries Ltd
Via
GlobeNewswire
Tickers
TEVA
Teva Announces Launch of $2,000,000,000 (Equivalent) Offering of Senior Notes
May 19, 2025
From
Teva Pharmaceutical Industries Ltd
Via
GlobeNewswire
Tickers
TEVA
Moody's Investor Services Upgrades Teva Amid Continued Success of Pivot to Growth Strategy
May 15, 2025
From
Teva Pharmaceutical Industries Ltd
Via
GlobeNewswire
Tickers
TEVA
Teva’s 2024 Healthy Future Report Highlights Sustainability Progress, Including Surpassed Targets Linked to Financial Strategy
May 12, 2025
From
Teva Pharmaceutical Industries Ltd
Via
GlobeNewswire
Tickers
TEVA
Teva Reports Ninth Consecutive Quarter of Growth in Q1 2025 With Key Innovative Medicines Growing ~40%; 2025 Profit Outlook Improved
May 07, 2025
From
Teva Pharmaceutical Industries Ltd
Via
GlobeNewswire
Tickers
TEVA
Teva to Host Innovation & Strategy Day on Thursday, May 29 in New York City
May 07, 2025
From
Teva Pharmaceutical Industries Ltd
Via
GlobeNewswire
Tickers
TEVA
Teva and Alvotech Announce FDA Approval of Interchangeability for SELARSDI™ (ustekinumab-aekn) with Stelara® (ustekinumab)
May 05, 2025
From
Teva Pharmaceutical Industries Ltd
Via
GlobeNewswire
Tickers
ALVO
TEVA
Teva Announces FDA Filing Acceptance for AJOVY® (fremanezumab) in Pediatric Episodic Migraine Prevention
April 07, 2025
From
Teva Pharmaceutical Industries Ltd
Via
GlobeNewswire
Tickers
TEVA
New Data Strengthens Teva’s Schizophrenia Portfolio, Including Phase 3 SOLARIS Trial Survey Results Demonstrating Patient and Healthcare Professional Satisfaction with TEV-'749 (olanzapine) as a Once-Monthly Subcutaneous Long-Acting Injectable
March 31, 2025
From
Teva Pharmaceutical Industries Ltd
Via
GlobeNewswire
Tickers
TEVA
Teva Releases Q1 2025 Aide Memoire
March 27, 2025
From
Teva Pharmaceutical Industries Ltd
Via
GlobeNewswire
Tickers
TEVA
Teva to Host Conference Call to Discuss First Quarter 2025 Financial Results at 8 a.m. ET on May 7, 2025
March 27, 2025
From
Teva Pharmaceutical Industries Ltd
Via
GlobeNewswire
Tickers
TEVA
Teva to Present at Barclays Global Healthcare Conference and Leerink Partners Global Healthcare Conferences in March
March 03, 2025
From
Teva Pharmaceutical Industries Ltd
Via
GlobeNewswire
Tickers
TEVA
2025 Community Routes: Access to Mental Health Care Grants Awarded to Clinics in Alabama, Mississippi, and Texas, Funded by Teva Pharmaceuticals
February 27, 2025
From
Teva Pharmaceutical Industries Ltd
Via
GlobeNewswire
Tickers
TEVA
Teva and Sanofi Present New Positive Phase 2b Study Results at ECCO 2025 Reinforcing Best-in-Class Potential of Duvakitug (Anti-TL1A) in Ulcerative Colitis and Crohn’s Disease
February 22, 2025
From
Teva Pharmaceutical Industries Ltd
Via
GlobeNewswire
Tickers
SNY
TEVA
Teva and Alvotech Announce SELARSDI™ (ustekinumab-aekn) Injection Now Available in the U.S.
February 21, 2025
From
Teva Pharmaceutical Industries Ltd
Via
GlobeNewswire
Tickers
ALVO
TEVA
Teva to Host Conference Call on February 24, 2025 to Discuss New Data Presented for Duvakitug (anti-TL1A) Positive Phase 2b results at the 20th Annual Congress of the European Crohn's and Colitis Organisation (ECCO)
February 18, 2025
From
Teva Pharmaceutical Industries Ltd
Via
GlobeNewswire
Tickers
TEVA
Teva Delivers Second Consecutive Year of Growth; Announces Strong Financial Results in Fourth Quarter and Full Year 2024, Led by Generics Performance and Innovative Portfolio Growth
January 29, 2025
From
Teva Pharmaceutical Industries Ltd
Via
GlobeNewswire
Tickers
TEVA
Teva Announces Collaboration to Commercialize Formycon’s Biosimilar Candidate to Eylea® (aflibercept) in major parts of Europe and in Israel
January 13, 2025
From
Teva Pharmaceutical Industries Ltd
Via
GlobeNewswire
Tickers
TEVA
Teva to Present at the 43rd Annual J.P. Morgan Healthcare Conference
December 23, 2024
From
Teva Pharmaceutical Industries Ltd
Via
GlobeNewswire
Tickers
TEVA
Teva to Host Conference Call to Discuss Fourth Quarter and Full Year 2024 Financial Results and 2025 Financial Guidance at 8 a.m. ET on January 29, 2025
December 20, 2024
From
Teva Pharmaceutical Industries Ltd
Via
GlobeNewswire
Tickers
TEVA
Teva and Sanofi Announce Duvakitug (Anti-TL1A) Positive Phase 2b Results Demonstrating Best-in-Class Potential in Ulcerative Colitis and Crohn’s Disease
December 17, 2024
From
Teva Pharmaceutical Industries Ltd
Via
GlobeNewswire
Tickers
TEVA
Teva Announces New Patient Access Program with Direct Relief to Provide Access to Inhalers for Uninsured Patients
December 11, 2024
From
Teva Pharmaceutical Industries Ltd
Via
GlobeNewswire
Tickers
TEVA
Teva Announces Agreement to Divest Teva-Takeda, its Business Venture in Japan
December 05, 2024
From
Teva Pharmaceutical Industries Ltd
Via
GlobeNewswire
Tickers
TEVA
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms Of Service
.